“Boehringer Ingelheim is pleased that the FDA has granted Breakthrough Therapy Designation to our investigational third-generation EGFR inhibitor BI 1482694. We feel this designation reflects the potential of the compound to be an important part of the treatment of non-small cell lung cancer in pat...
That, to me, is a breakthrough, and it will change the way we do adjuvant treatment. And I think we’re going to see similar data for other molecular alterations. More importantly, we will see data for immunotherapy in the early-stage settings. So I think, again, that how you apply ...
Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough? J Thorac Oncol 2014; 9: 7-17.T. Sourisseau, K.A. Hassan, I. Wistuba, et al., "Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a ...
Importantly, T-DXd has achieved a breakthrough that has dramatically transformed the therapeutic landscape of these patients. Pan-HER TKIs Early attempts to target HER2 mutations in pretreated patients with NSCLC were made with pan-HER TKIs, such as afatinib, neratinib, and dacomitinib. However, ...
OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Review Osimertinib making a breakthrough in lung cancer targeted therapy This article was published in the following Dove Press journal: OncoTargets and Therapy 6 September 2016 Number of ...
As with many cancers, the best treatment for lung cancer is prevention. Reducing your risk of lung cancer through smoking cessation, avoiding secondhand smoke, partaking in regular exercise, staying active, and keeping a balanced diet, can go a long way in lung cancer prevent...
New therapies have become available in the past 5-10 years that can dramatically change the prognosis for patients. These breakthrough treatments plus healthier lifestyle choices are making it possible for patients to live longer than ever before with advanced-stage lung cancer. ...
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon 20 ...
Unlocking the Secret: How One Protein Can Halt Lung Cancer Spread December 14, 2023 The findings could lead to the development of a new anti-cancer drug and more personalized… Health Mount Sinai Lung Cancer Breakthrough: Allergy Medicine’s Unexpected Role in Treatment December 8, 2023 A Mou...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated wit